Pacira BioSciences (PCRX) CEO receives 261,818 stock units award

Rhea-AI Filing Summary

Pacira BioSciences, Inc. reported an equity award to its Chief Executive Officer and director, Frank D. Lee. On February 11, 2026, he acquired 261,818 shares of common stock in the form of restricted stock units granted at a price of $0 per share.

These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. Following this grant, Lee beneficially owns 660,830.841 shares of Pacira common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lee Frank D.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	261,818	$0.00	--

Holdings After Transaction: Common Stock — 660,830.841 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Frank D.

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUTE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		261,818(1)	A	$0	660,830.841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for its CEO?

Pacira BioSciences reported that CEO and director Frank D. Lee received an equity award. On February 11, 2026, he was granted 261,818 restricted stock units representing Pacira common shares, as disclosed in a Form 4 insider transaction filing with the SEC.

How many Pacira (PCRX) shares were granted to CEO Frank D. Lee and at what price?

Frank D. Lee received 261,818 restricted stock units tied to Pacira common stock. The award was granted at a price of $0 per share, indicating a compensatory equity grant rather than an open-market purchase of the company’s stock.

When do the Pacira (PCRX) restricted stock units granted to the CEO vest?

The restricted stock units vest in four equal annual installments starting February 15, 2027. Each installment requires that Frank D. Lee remain in continuous service with Pacira BioSciences through the applicable vesting date to receive the underlying common shares.

How many Pacira (PCRX) shares does the CEO own after this Form 4 transaction?

After the reported grant, Frank D. Lee beneficially owns 660,830.841 shares of Pacira common stock. This total reflects his direct ownership following the acquisition of 261,818 restricted stock units reported in the February 11, 2026 Form 4 filing.

What does each restricted stock unit in the Pacira (PCRX) CEO grant represent?

Each restricted stock unit represents a contingent right to receive one share of Pacira common stock. Actual delivery of shares depends on the units vesting over four annual installments and on Frank D. Lee maintaining continuous service with the company through each vesting date.